Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions - The REALITY trial: A randomized controlled trial

JAMA

Volumn 295, Issue 8, 2006, Pages 895-904

  Morice, Marie Claude ^a,i   Colombo, Antonio ^b   Meier, Bernhard ^c   Serruys, Patrick ^d   Tamburino, Corrado ^e   Guagliumi, Giulio ^f   Sousa, Eduardo ^g   Stoll, Hans Peter ^h  

^a INSTITUT CARDIOVASCULAIRE PARIS SUD   (France)

^b EMO GVM CENTRO CUORE COLUMBUS   (Italy)

^c UNIVERSITY OF BERN   (Switzerland)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e Ferrarotto Hospital   (Italy)

^f OSPEDALI RIUNITI   (Italy)

^g INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

^h Cordis Clinical Research Europe ^*  (Belgium)

ⁱ INSTITUT HOSPITALIER JACQUES CARTIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; RAPAMYCIN;

ADULT; ANGINA PECTORIS; ANGIOGRAPHY; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG ELUTING STENT; DRUG FATALITY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; Q WAVE; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; REVASCULARIZATION; RISK FACTOR; THROMBOSIS;

EID: 33644532583     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.295.8.895     Document Type: Article

References (23)

1. Morice MC, Serruys PW, Sousa JE, et al; RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-1780.
2. Moses JW, Leon MB, Popma JJ, et al; SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-1323.
3. Schofer J, Schluter M, Gershlick AH, et al; E-SIRIUS Investigators. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet. 2003;362:1093-1099.
4. Schampaert E, Cohen EA, Schluter M, et al; C-SIRIUS Investigators. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol. 2004;43:1110-1115.
5. Fajadet J, Morice MC, Bode C, et al. Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial. Circulation. 2005;111:1040-1044.
6. Grube E, Silber S, Hauptmann KE, et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003;107:38-42.
7. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. 2003;108:788-794.
8. Stone GW, Ellis SG, Cox DA, et al; TAXUS-IV Investigators. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation. 2004;109:1942-1947.
9. Stone GW, Ellis SG, Cox DA, et al; TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221-231.
10. Perin EC. Choosing a drug-eluting stent: a comparison between CYPHER and TAXUS. Rev Cardiovasc Med. 2005;6(suppl 1):S13-S21.
11. Campeau L. Grading for angina pectoris [letter]. Circulation. 1976;54:522-523.
12. Braunwald E. Unstable angina: a classification. Circulation. 1989;80:410-414.
13. Serruys PW, Foley DP, de Feyter PJ, eds. Quantitative Coronary Angiography in Clinical Practice. Dordrecht, the Netherlands: Kluwer Academic; 1994.
14. Mauri L, Orav EJ, O'Malley J, et al. Relationship of late loss in lumen diameter to coronary restenosis in sirolimus-eluting stents. Circulation. 2005;111:321-327.
15. Edelman ER, Rogers C. Stent-versus-stent equivalency trials: are some stents more equal than others? Circulation. 1999;100:896-898.
16. Hausleiter J, Kastrati A, Mehilli J, et al. Impact of lesion complexity on the capacity of a trial to detect differences in stent performance: results from the ISAR-STEREO trial. Am Heart J. 2003;146:882-886.
17. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126-2130.
18. Ong AT, Serruys PW, Aoki J, et al. The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) Registry. J Am Coll Cardiol. 2005;45:1135-1141.
19. Goy JJ, Stauffer JC, Siegenthaler M, Benoit A, Seydoux C. A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXi trial. J Am Coll Cardiol. 2005;45:308-311.
20. Kastrati A, Mehilli J, von Beckerath N, et al; ISAR-DESIRE Study Investigators. Sirolimus-eluting stent or paclitaxel-eluting stent versus balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA. 2005;293:165-171.
21. Kastrati A. Paclitaxel-eluting stent versus sirolimus-eluting stent for the prevention of restenosis in diabetic patients with coronary artery disease (ISAR-DIABETES). Paper presented at: 2005 Scientific Session of the American College of Cardiology; March 6, 2005; Orlando, Fla.
22. Windecker S, Remondino A, Wenaweser P, et al. A randomized comparison of a sirolimus with a paclitaxel eluting stent for coronary revascularization: the SIRTAX trial [abstract]. J Am Coll Cardiol. 2005;45(suppl A):7A.
23. Kastrati A, Dibra A, Eberle S, et al. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA. 2005;294:819-825.